课题基金 / 基金详情

Hyperbaric Oxygenation May Increase Lung Injury

Hyperbaric Oxygenation May Increase Lung Injury
高压氧可能会增加肺损伤
批准号:
7229973
负责人:
Michail Sitkovsky
金额:
$19.06万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-05-01 至 2008-04-30

项目摘要

项目成果

Michail Sitkovsky的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):高压氧治疗(HBOT)是基础生物医学研究人员和补充和替代医学(CAM)从业者感兴趣的。HBOT被应用于各种各样的疾病,这些疾病的症状是目标组织中的缺氧。由于缺乏对潜在生理学的了解,它还没有被美国医学界接受作为一种治疗方法,而且还没有仔细评估潜在的危险。需要进行广泛的临床前研究,以克服目前对HBOT的偏见并确定其局限性。这项建议的中心目标是了解HBOT有益效果的机制,并确定其潜在危险。我们最近发现了低氧驱动和A2A型和A2B型腺苷受体(A2AR/A2BR)介导的通路在抑制过度活跃的炎症细胞和保护缺氧性炎症区域正常组织中的关键作用。我们推测,在HBOT过程中,氧气消除这一机制可能解释了HBOT通过“去抑制”的免疫细胞清除感染的有益效果。我们还担心,HBOT削弱这一保护机制可能会导致炎症组织损伤的意外加剧。我们计划在HBOT治疗的野生型小鼠和在不同肺部炎症模型中A2AR和/或A2BR基因完全和组织特异性缺失的独特小鼠的研究中验证我们的假设。我们的具体目标#1和2是在吸入性和静脉注射诱导的小鼠肺损伤模型研究中测试HBOT是否会加剧肺部炎症,而在目标#3中,我们将测试A2AR激动剂的代偿治疗是否会防止HBOT加剧炎性肺损伤,以便获得HBOT在CAM和其他治疗中的其他适应症的潜在好处。
英文摘要
DESCRIPTION (provided by applicant): Hyperbaric Oxygen therapy (HBOT) is of interest to basic biomedical researchers and to practitioners of complementary and alternative medicine (CAM). HBOT is applied to a wide variety of diseases with symptoms caused by a lack of oxygen in the target tissues. It is not accepted as a treatment by the US medical community due to the lack of understanding of the underlying physiology and yet to be carefully evaluated potential dangers. Extensive pre-clinical studies are required to overcome the current bias towards HBOT and to determine its limitations. The central goal of this proposal is to understand the mechanisms of beneficial effects of HBOT and to identify its potential dangers. We recently established the critical role of the hypoxia-driven and A2A and A2B adenosine receptor (A2AR/A2BR)-mediated pathway in inhibition of overactive inflammatory cells and protection of normal tissues in hypoxic inflamed areas. We hypothesize that the elimination of this mechanism by oxygen during HBOT may explain the beneficial effects of HBOT in clearing infections by "de-inhibited" immunocytes. We are also concerned that the weakening of this protective mechanism by HBOT may lead to an unintended exacerbation of inflammatory tissue damage. We plan to test our hypothesis in studies of HBOT-treated wild type mice and of unique mice with total and tissue-specific deletion of A2AR and/or A2BR genes in different models of lung inflammation. Our specific aims #1 and 2 are to test whether HBOT exacerbates lung inflammation in studies of inhalative and intravenously induced models of lung injury in mice, while in Aim #3 we will test whether compensatory treatment with A2AR agonist will prevent the inflammatory lung injury exacerbation by HBOT in order to gain potential benefits of HBOT for other indications in CAM and other therapies.
期刊论文(4)
专著(0)
科研奖励(0)
会议论文
DOI: 10.4049/jimmunol.1001567
发表时间: 2011-02-15
期刊: Journal of immunology (Baltimore, Md. : 1950)
影响因子: --
作者: [Belikoff BG, Hatfield S, Georgiev P, Ohta A, Lukashev D, Buras JA, Remick DG, Sitkovsky M]
通讯作者: Sitkovsky M
DOI: 10.1097/shk.0b013e3182085f12
发表时间: 2011-04
期刊: Shock (Augusta, Ga.)
影响因子: --
作者: [Belikoff B, Hatfield S, Sitkovsky M, Remick DG]
通讯作者: Remick DG
DOI: 10.1371/journal.pone.0000853
发表时间: 2007-09-05
期刊: PloS one
影响因子: 3.7
作者: [Thiel M, Caldwell CC, Kreth S, Kuboki S, Chen P, Smith P, Ohta A, Lentsch AB, Lukashev D, Sitkovsky MV]
通讯作者: Sitkovsky MV
[5,10,15,20-Tetra-kis(4-chloro-phen-yl)porphyrinato]bis-(tributyl-phosphine)cobalt(III) perchlorate.
[5,10,15,20-四-(4-氯-苯基)卟啉]双-(三丁基膦)钴(III)高氯酸盐。
DOI: 10.1107/s1600536809019163
发表时间: 2009
期刊: Acta crystallographica. Section E, Structure reports online
影响因子: --
作者: [Etemadi,Bijan, Kia,Reza, Asadi,Mozaffar, Mohammadi,Kh]
通讯作者: Mohammadi,Kh
Preventing the Hypoxia-Adenosinergic Inhibtion of Anti-HIV Immune Response
  • 批准号:
    8043237
  • 项目类别:
  • 资助金额:
    $28.45万
  • 财政年份:
    2010
  • 负责人:
    Michail Sitkovsky
  • 依托单位:
"Cancer Immunotherapy by Targeting A2 Adenosine Receptor"
  • 批准号:
    7100600
  • 项目类别:
  • 资助金额:
    $22.29万
  • 财政年份:
    2006
  • 负责人:
    Michail Sitkovsky
  • 依托单位:
"Cancer Immunotherapy by Targeting A2 Adenosine Receptor"
  • 批准号:
    7409103
  • 项目类别:
  • 资助金额:
    $21.65万
  • 财政年份:
    2006
  • 负责人:
    Michail Sitkovsky
  • 依托单位:
Cancer Immunotherapy by Targeting A2 Adenosine Receptor
  • 批准号:
    8464014
  • 项目类别:
  • 资助金额:
    $20.15万
  • 财政年份:
    2006
  • 负责人:
    Michail Sitkovsky
  • 依托单位:
海外基金